Advertisement
UK markets close in 7 hours 38 minutes
  • FTSE 100

    8,289.91
    +76.42 (+0.93%)
     
  • FTSE 250

    20,360.49
    +195.95 (+0.97%)
     
  • AIM

    776.59
    +5.06 (+0.66%)
     
  • GBP/EUR

    1.1647
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.2539
    -0.0024 (-0.19%)
     
  • Bitcoin GBP

    50,867.36
    -537.98 (-1.05%)
     
  • CMC Crypto 200

    1,370.33
    +5.20 (+0.38%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CRUDE OIL

    78.45
    -0.03 (-0.04%)
     
  • GOLD FUTURES

    2,329.10
    -2.10 (-0.09%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,468.52
    -109.78 (-0.59%)
     
  • DAX

    18,243.83
    +68.62 (+0.38%)
     
  • CAC 40

    8,032.42
    +35.78 (+0.45%)
     

Is CRISPR Therapeutics Stock a Buy Now?

Is CRISPR Therapeutics Stock a Buy Now?

A year ago, CRISPR Therapeutics' (NASDAQ: CRSP) stock was trading for $46 per share. As of Tuesday afternoon, the biotech stock was at $64. While other investors have begun to catch on to the upside of the company, it's still a clinical-stage biopharmaceutical company -- that is, one with no marketed therapies yet.